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vasospasm following traumatic subarachnoid
hemorrhage
Oliver Lasry and Judith Marcoux*Abstract
Introduction: Traumatic subarachnoid hemorrhage (SAH) is a common intracranial lesion after traumatic brain injury
(TBI). As in aneurysmal SAH, cerebral vasospasm is a common cause of secondary brain injury and is associated with
the thickness of traumatic SAH. Unfortunately, there is limited literature on an effective treatment of this entity. The
vasodilatory and inotropic agent, Milrinone, has been shown to be effective in treating vasospasm following aneurysmal
SAH. The authors hypothesized that this agent could be useful and safe in treating vasospasm following tSAH.
Case descriptions: Case reports of 2 TBI cases from a level 1 trauma centre with tSAH and whom developed delayed
ischemic neurological deficits (DINDs) are presented. Intravenous Milrinone treatment was provided to each patient
following the “Montreal Neurological Hospital Protocol”.
Discussion and evaluation: Both patients had an improvement in their DINDs following the treatment protocol. There
were no complications of treatment and the Glasgow Outcome Scores of the patients ranged from 4 to 5.
Conclusion: This is the first report of the use of intravenous Milrinone to treat cerebral vasospasm following traumatic
SAH. This treatment option appeared to be safe and potentially useful at treating post-traumatic vasospasm. Prospective
studies are necessary to establish Milrinone’s clinical effectiveness in treating this type of cerebral vasospasm.
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The most frequent cause for subarachnoid hemorrhage
(SAH) is traumatic brain injury (TBI) (Eisenberg et al.
1990). Amongst TBI patients, traumatic subarachnoid
hemorrhage (tSAH) is one of the commonest traumatic
brain lesions (Chieregato et al. 2005). The literature has
described that TBI patients with tSAH have worse out-
comes compared to those without this lesion (Kakarieka
et al. 1994, 1995). Cerebral vasospasm and delayed
ischemia have been shown to be a key process leading
to these inferior patient outcomes, which occur in up
to 40% of severe TBI patients (Lin et al. 2012; Zurynski
and Dorsch 1998). Moreover, the pathophysiology of
vasospasm following tSAH is similar to the one occur-
ring after aneurysmal SAH (aSAH) (Wilkins and Odom
1970; Werner and Engelhard 2007). The incidence of* Correspondence: judith.marcoux@mcgill.ca
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reproduction in any medium, provided the origcerebral vasospasm after tSAH is strongly related to the
thickness of the SAH. In fact, the latter was correlated
to the Fisher Classification commonly used to predict
the risk of vasospasm after aSAH (Chieregato et al. 2005;
Taneda et al. 1996). Despite the similarities between these
two subtypes of SAH, there has been limited investigation
in cerebral vasospasm occurring after tSAH.
Calcium channel blockers are effective in improving
outcomes in TBI patients with tSAH (Langham et al.
2003). Other than this established neuroprotective strategy,
patients with tSAH are currently being treated based
on data extrapolated from the aSAH literature, which
includes the potentially harmful effects of Triple-H Therapy
(Zurynski and Dorsch 1998). The unfavorable effects of this
therapy in TBI patients relates to the difficulty these
patients have in tolerating excessive fluid volume and a
low hematocrit. These physiological maneuvers increase
the possibility of a secondary brain injury by increasing
intracranial pressure and lowering oxygen delivery tohis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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Montreal Neurological Hospital Protocol” to treat patients
with cerebral vasospasm following aSAH. Briefly, their
protocol uses intravenous milrinone and the maintenance
of homeostasis to control symptomatic vasospasm follow-
ing aSAH. Given the similarities between the vasospasm
occurring after aSAH and tSAH, the authors hypothesized
that maintenance of physiologic homeostasis and the con-
current use of intravenous Milrinone, as per the “Montreal
Neurological Hospital Protocol”, was a potentially effective,
safe and appropriate management strategy for TBI patients
who develop cerebral vasospasm from tSAH.
Case descriptions
We are presenting 2 case reports of patients who pre-
sented to a level 1 trauma centre with a diagnosis of
tSAH who subsequently developed delayed ischemic
deficits during their admission and were thereafter
treated with intravenous Milrinone. The severity of the
TBI was classified using the GCS. Once delayed ischemic
symptoms started, each patient was transferred to the
ICU for neuromonitoring and initiation of intravenous
Milrinone. They both had a central venous catheter
inserted on arrival to the ICU to monitor their volume
status with their central venous pressure as a surrogate.
“The Montreal Neurological Hospital Protocol” described
by Lannes et al. (2012) was followed strictly in the treat-
ment of all patients included in this case report. The
protocol initially focuses on excluding other etiologies for
the delayed ischemic deficits such as metabolic/electrolyte
abnormalities, hydrocephalus, recurrent hemorrhage,
seizures or infection. Thereafter, a plain CT of the head
is performed. Once these investigations reveal no other
cause for the neurological deterioration, radiological con-
firmation of the vasospasm with either transcranial dop-
pler, CTA or DSA is completed. The first Milrinone bolus
is then administered (0.1 mg/kg) and the intensive care
team ensures that the patients’ deficits improve or revert
before starting a maintenance infusion (0.75 μg/kg/min).
Normal saline boluses (0.9% NS) are used for any patients
who have a central venous pressure below 6 mmHg. The
use of intravenous norepinephrine is only employed if the
patient’s blood pressure falls below their baseline, as
recorded during their admission before being transferred
to the ICU. Once the patients have their delayed ischemic
deficits reversed/improved for at least 48 hours, weaning
of the Milrinone infusion is started by reducing the dose
by 0.25 μg/kg/min decrements. If there are any recurrent
DINDs, the patients are placed back on the dose they were
previously receiving. If required, another Milrinone bolus
is administered if the patient’s deficits do not revert. At
our institution, all TBI patients who have a tSAH with
Fisher Grade 3 or above are treated with Nimodipine
(60 mg orally once daily for 21 days) (Harders et al. 1996;Rosen and Macdonal 2005). Therefore, Nimodipine treat-
ment was part of the treatment protocol for all the cases
presented. In addition, each patient had either a CTA or
MR-Angiography of the brain, at baseline, to exclude a
causative vascular lesion for the SAH. No patient in this
report had such lesion. The 6-month functional outcome
of patients was determined using the GOS. Table 1 sum-
marizes the clinical evolution of the 2 patients included
in this report. As per institutional guidelines, the charts
review and reports are approved by the Director of
Professional Services.
Case 1
History
The first case is a 64 year-old male who was previously
known for cerebral abscess, which resulted in chronic
epilepsy. His medication profile consisted only of Carba-
mazepine. He presented to our trauma centre after having
a generalized tonic-clonic seizure resulting in a witnessed
fall from his own height.
Examination and clinical course
On arrival, his Glasgow Coma Score (GCS) (Teasdale and
Jennett 1974) was 14 with disorientation to time and place.
The rest of his neurological exam was non-localizing and
his hemodynamic status was stable. His initial computed
tomography (CT) of the head revealed a thick collection
of subarachnoid hemorrhage localized to the left sylvian
fissure (Figure 1). During the first 3 days of admission his
neurological status had normalized. Eight days after the
trauma, the patient’s wife noted that his neurological
status had changed. She therefore brought him back to
the emergency room where he was found to have a right-
sided hemiparesis, a right lower facial droop, dysarthria
and global aphasia. He was immediately admitted to the
Intensive Care Unit (ICU) for neuro-monitoring. A mag-
netic resonance imaging of the brain revealed restricted
diffusion in the left MCA territory consistent with a sub-
acute infarct (Figure 2). Thereafter, the Milrinone protocol
was started and within 90 minutes, the patient’s symptoms
had improved. The patient had a formal (Digital Subtrac-
tion Angiography) DSA that confirmed vasospasm of the
M1 and M2 segments of the left middle cerebral artery
(MCA) (Figure 3). The protocol was continued for a total
of 9 days and the weaning of Milrinone started on the 5th
day. The patient was discharged from hospital with a
slight expressive aphasia and right hemiparesis, which was
improved from his initial presentation.
Case 2
History
The second case is a 64 year-old female, with a past
medical history of alcoholism, who presented to our
Table 1 Summary of case reports
Case number 1 2
Age (years) 64 64
Medical history Cerebral abscess, epilepsy Alcoholism
Mechanism of injury Fall from own height Fall from own height
Initial GCS 14 14
Initial CT-Head finding SAH in left sylvian fissure Diffuse SAH, concentrated in left sylvian fissure
Fisher grade of SAH 3 3
Onset of DINDs (after admission) 8 7
Presenting symptoms Aphasia, right hemiparesis Aphasia, dysarthria, lethargy, right hemiparesis
Imaging modality to investigate vasospasm DSA CTA
Duration of Milrinone treatment/ICU stay (days) 9 10
Recurrence of DINDs No Yes
GOS at 6 months 4 5
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falling from her own height.
Examination and clinical course
On arrival, her vital signs were stable and she had a
GCS of 14. A CT-head was completed which revealedFigure 1 Initial CT-Head reveals SAH concentrated in the left sylvian fdiffuse and thick subarachnoid hemorrhage, which was
mainly centered over the left sylvian fissure and convexity
(Figure 4). The patient’s GCS was 15 without any neuro-
logical deficits within 36 hours of her admission. On the
7th day post-trauma, she was found to be somnolent,
expressively aphasic, dysarthric and weak on her rightissure with a thickness of > 1.0 mm (Fisher Grade 3).
Figure 2 DWI MRI sequence completed once the patient presented with delayed ischemic symptoms. There is evidence of restricted diffusion
in DWI with hyperintensity in the ADC map (not shown) in the same left middle cerebral artery vascular territory, indicating early subacute infarction.
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ferred to the ICU and had a CT-Angiography (CTA) that
revealed focal narrowing of the M1 and M2 segments of
the left MCA. She was therefore started on the Milrinone
protocol. Her delayed ischemic deficits completely resolved
within 2 hours. Weaning of the drug started 4 days after
her ICU admission. She was slowly weaned off Milrinone
over 6 days due to recurrence of DINDs. She had no
residual deficits after her discharge from the ICU.
Discussion and evaluation
Historically, the literature on the identification and treat-
ment of cerebral vasospasm after tSAH has been limited.
In the last two decades, there has been a significant rise
in the description of this phenomenon. Despite these
advances, the literature’s recommendations on the man-
agement of these patients are based on extrapolating
data from the literature of vasospasm after aSAH. This
type of approach is intuitively appealing because of the
similarities in pathophysiology that have been shownbetween the two entities (Wilkins and Odom 1970; Werner
and Engelhard 2007). tSAH thickness and severity has been
consistently shown to be a risk factor for the development
of cerebral vasospasm after TBIs (Zubkov et al. 2000). The
development of delayed ischemia in these last patients has
been shown to be almost identical to patients who suffered
an aSAH. Taneda et al. showed that patients with higher-
grade tSAH on the Modified Fisher Scale had an increased
risk of vasospasm and delayed ischemia (Taneda et al.
1996). These episodes peaked between post-trauma days 4
to 16, just as described in aSAH. However, there are subtle
differences between the two processes. TCD studies have
revealed that patients with TBI develop cerebral vasospasm
earlier than patients with aSAH (Taneda et al. 1996; Lee
et al. 1997; Oertel et al. 2005; Servadei et al. 2002). This
earlier onset, usually within 48 hours, is explained by
the fact that TBI patients have traumatic forces applied
to their cerebral vessels at the time of injury and a
release of vasoactive substance from injured brain that
can induce earlier vasospasm (Zurynski and Dorsch 1998).
Figure 3 DSA confirming vasospasm in the narrowed M1 and M2 segments (indicated by the arrow) of the left middle cerebral artery.
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develop cerebral vasospasm is still not established. Studies
investigating tSAH have shown that this lesion predicts
worse outcomes but that it may be related to a multitude
of causes, such as: progression of other traumatic hemato-
mas, older age and the severity of the initial injury
(Chieregato et al. 2005; Servadei et al. 2002). Evidently,
there is still a significant lack of knowledge pertaining
to the pathophysiology and natural history of cerebral
vasospasm after tSAH. Still, there is enough evidence
supporting that cerebral vasospasm can contribute to
secondary brain injury in TBI patients and that treat-
ment measures should be sought.
As mentioned earlier, the treatment of this vasospasm
has been undertaken by implementing similar strategies
as in aSAH. A Cochrane Review of six randomized-
controlled trials on the use of Nimodipine in TBI showed
that the subgroup of patients with tSAH had a decreased
risk of death and severe disability compared to placebo
(Langham et al. 2003). There was the added caution of an
increased risk of hypotension in these treated patients
that may worsen outcome. Our 2 patients were treated
with Nimodipine. They did not develop hypotension, yetNimodipine was not sufficient to prevent clinically signifi-
cant vasospasm. In contrast, traditional treatment with
Triple-H therapy has been tried in the tSAH popula-
tion with poor results and treatment efficacy (Zurynski
and Dorsch 1998; Oertel et al. 2005). Furthermore, TBI
patients may have other traumatic lesion such as contu-
sions, which may be at-risk of progressing if hypertensive
therapy is started. Also, hypervolemia can worsen cases of
post-traumatic cerebral edema (Oertel et al. 2005). There
have been case reports of using endovascular therapies for
cerebral vasospasm after tSAH. Intra-arterial papaverine
therapy and balloon dilatation angioplasty were somewhat
successful in these instances, but come with the risk of
an endovascular approach such as ischemic stroke (Newell
et al. 1992; Vardiman et al. 1995). Despite having described
adequate neuroprotective measures for vasospasm after
tSAH, the literature has not described any other effective
treatments to reverse this clinical entity. Milrinone is a
potent phosphodiesterase Type III inhibitor with both
inotropic and vasodilatory properties and perhaps anti-
inflammatory properties at the level of the cerebral vessel’s
wall (Lannes et al. 2012, Vardiman et al. 1995; Hayashida
et al. 1999; Vroom et al. 1996). It has a concentration-
Figure 4 CT-Head demonstrating diffuse subarachnoid hemorrhage in bilateral basal cisterns which is mainly concentrated in the left
sylvian fissure (Fisher Grade 3).
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at sufficient concentration (Nishiguchi et al., 2010). Given
the knowledge of the pathophysiology of vasospasm after
tSAH mentioned previously, Milrinone appears to be a
suitable therapy for this patient population. The “Montreal
Neurological Hospital Protocol’s use of homeostasis and
Milrinone avoids all of the potential complications that
Triple-H therapy can cause in TBI patients. In addition,
this type of approach most often avoids the need for any
endovascular therapy that requires a potentially unstable
patient to leave the ICU (Lannes et al. 2012). In the
two patients we treated, there were no complications of
treatment cases and all patients had good neurological
outcomes based on their 6-month Glasgow Outcome
Scale (GOS) (Jennett and Bond 1975).
Trauma centers have not uniformly adopted protocols
for the detection of vasospasm in patients with TBI. The
most recent Brain Trauma Foundation Guidelines do
not refer to this potentially treatable pathology (Bratton
et al. 2007). The literature has referred to using TCD,
CTA and DSA (Zurynski and Dorsch 1998). Neurological
examination may be a reliable indicator as to whendelayed ischemic symptoms begin in patients with mild
TBI. In cases of moderate to severe TBI patients, this type
of examination may be impossible because the patient’s
neurological status is severely compromised. The clinician
may therefore miss subtle deficits that may occur with
vasospasm and delayed ischemia. For this reason, surveil-
lance protocols with radiological exams and/or electro-
encephalographic monitoring are of utmost importance
for detecting vasospasm in these patients. Unfortunately,
there is no existing consensus in the literature regarding a
specific protocol to follow.
There are limitations to extrapolating any conclusions
based on these case reports. As Lannes et al. mention,
there are many factors that can cause symptoms similar
to DINDs in the context of SAH (Lannes et al. 2012). We
attempted to exclude these other causes by completing
the appropriate biochemical and imaging investigations.
Despite these limitations, we believe that in mild TBI
patients, clinical examinations can be quite informative in
terms of formulating a diagnosis of cerebral vasospasm.
Further studies are necessary to quantify the beneficial
effect of Milrinone on cerebral vasospasm after tSAH,
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to severe TBI cases, as well as both surgically and medic-
ally treated cases.
Conclusions
This report served to describe a possible treatment avenue
for cerebral vasospasm after tSAH using intravenous
Milrinone and homeostatic maneuvers, which differs
from what is currently offered in the literature. This
treatment modality appeared safe for TBI patients. It
also was effective in conjunction with Nimodipine for
our patients. Further prospective studies investigating
appropriate surveillance protocols for patients with TBI
who are at-risk for developing vasospasm are necessary.
Only then can further studies investigating the use of
Milrinone, in addition to other possible treatment mea-
sures, be completed to establish the management of
this type of secondary brain injury.
Consent
The written consent was obtained from one of the
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